CClinicalTrials.gg
Status unknownNCT03297736Updated Sep 24, 2020

Improved Otologic Implants on Demand Intraoperatively With 3D CAD/CAM Autografts

An interventional study of 3D CAD/CAM autograft prosthesis and Control device in Middle Ear Disease, sponsored by Nitinetics LLC. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-24.

Sponsored by Nitinetics LLC · Not applicable, Interventional, and Device feasibility

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Prospectively analyze the use of 3D subtraction CAD/CAM in the operating room environment. Study participants, requiring middle ear surgery and ossicular reconstruction, will be implanted with one of two middle ear implants. The rationale is to complete a pilot study of the technology with a small number of designs. Each implant will be commonly used, in the public domain, and recreated by the CAD/CAM software.

Read the detailed description

Conventional middle ear prosthetic prosthetics, including total ossicular replacement prostheses (TORPs) and partial ossicular replacement prostheses (PORPs) are expensive, require large inventories for otologic surgery services, and carry the risk of extrusion or rejection. Autologous bone and cartilage can be used for many of these applications, but it requires expensive operating room time for carving to the appropriate shape and size.

The above considerations led to the concept of subtractive 3D CAD/CAM (computer assisted design/computer assisted manufacture) to produce accurate bone and cartilage autografts on demand in the operating room. Such a technology is hypothesized to save money by reducing operating room time, and reducing the need for expensive inventories of various shapes, sizes, and types of prosthetic devices. Since autologous materials are hypothesized to be less likely to extrude or cause other problems such as infection, this could also reduce costs.

02

Conditions studied

  • Middle Ear Disease

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • at least 18 years of age with middle ear disease requiring surgical ossicular reconstruction

Exclusion criteria

Exclusion Criteria:

  • congenital anomalies
04

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    Control

    Subjects receive the control device.

    Device: Control device

  • Experimental
    Investigational device

    Subject receives the 3D CAD/CAM autograft prosthesis implant.

    Device: 3D CAD/CAM autograft prosthesis

Interventions

  • Device3D CAD/CAM autograft prosthesis

    Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.

  • DeviceControl device

    Surgical ossicular reconstruction with the standard available middle ear prosthesis.

05

What researchers measure

Primary outcomes

  1. Cost savings

    operative costs compared between treatment groups utilizing total operative time in minutes

    Time frame: perioperative

Secondary outcomes

  1. Number of participants with treatment related adverse events as assessed by CTCAE v4.0

    infectious process involving the use of a medical device

    Time frame: 6 months

  2. ABG

    mean air-bone gap assessed and compared between treatment groups for statistical significance

    Time frame: preoperative; 6weeks, 3 months, and 6 months postoperatively.

  3. Number of participants that experience device rejection

    rejection of device/prosthesis

    Time frame: 6 months

06

Study locations

1 of 1 sites recruiting
  • University of Florida-Jacksonville
    Jacksonville, Florida 32209, United States
    Recruiting
07

Registry details

Key details

Study ID
NCT03297736
Lead sponsor
Nitinetics LLC
Responsible party
Sponsor
First posted
Sep 29, 2017
Start date
Mar 1, 2016
Primary completion
Mar 31, 2021 (estimated)
Completion
Mar 31, 2023 (estimated)
Last update
Sep 24, 2020

Study contacts

Glenn Knox, M.D., J.D.
Contact
Glenn.Knox@jax.ufl.edu
(904) 244-3498
Alisa Knox
Contact
alisa102189@yahoo.com
Glenn Knox, M.D., J.D.
principal investigator · Nitinetics LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion